Celgene
BMS finally gets FDA OK for liso-cel, sets $410k launch price
Phil Taylor
Breyanzi, Bristol-Myers Squibb, Celgene, cell therapy, DLBCL, immuno-oncology, liso-cel, non-Hodgkin lymphoma, Oncology, TG Therapeutics, Ukoniq
0 Comment
NICE reverses stance on Celgene’s Revlimid for myeloma maintenance
Phil Taylor
Bristol-Myers Squib, Cancer Drugs Fund, Celgene, Haematology, multiple myeloma, NHS, NICE, Oncology, Revlimid, UK
0 Comment
BMS/Celgene merger payout evaporates as CVR deadline passes
Phil Taylor
Bristol-Myers Squibb, Celgene, Financial, M&A
0 Comment
News/ News/ Sales and Marketing/ Top stories
Fresh doubts over BMS’ merger payout as FDA delays key drug review
Richard Staines
Bristol-Myers Squibb, cancer, Celgene, Sanofi
0 Comment
News/ News/ Sales and Marketing
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Phil Taylor
Bristol-Myers Squibb, Celgene, fda, liso-cel, manufacturing
0 Comment
FDA’s review date for BMS’ ide-cel sneaks under the CVR wire
Phil Taylor
Bristol-Myers Squibb, CAR T, Celgene, cell therapy, immuno-oncology, Oncology, regulatory
0 Comment
Market Access/ News/ News/ News/ Oncology
Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file
Phil Taylor
Bristol-Myers Squibb, Celgene, Financial, investors, Mergers and acquisitions
0 Comment
Concerns over BMS and Celgene merger payout as FDA extends drug review
Richard Staines
blood cancer, Bristol-Myers Squibb, cancer, CAR T, Celgene, liso-cel
0 Comment